GlaxoSmithKline, widely criticized for its handling of information about its major antidepressant drug, Paxil, announced it will post clinical trials results for all its marketed drugs on a company Web site. GSK said the site will include results of all tests run on a drug before its approval, as well as any additional tests devised for new uses after a drug goes to market. Last week, the company posted on its site all test reports on Paxil and its effect on children and adolescents, including indications it caused suicidal tendencies in some patients, and indicated it would expand the move to include other drugs.

Full Story:

Related Summaries